The role of free to total PSA ratio in prediction of extracapsular tumor extension and biochemical recurrence after radical prostatectomy in patients with PSA between 4 and 10 ng/ml-Reference-Cited by-同舟云学术

The role of free to total PSA ratio in prediction of extracapsular tumor extension and biochemical recurrence after radical prostatectomy in patients with PSA between 4 and 10 ng/ml

Published:2012-02-08 Issue:4 Volume:44 Page:1031-1038
ISSN:0301-1623
Container-title:International Urology and Nephrology
language:en
Short-container-title:Int Urol Nephrol

Author:

Masieri Lorenzo,Minervini Andrea,Vittori Gianni,Lanciotti Michele,Lanzi Federico,Lapini Alberto,Carini Marco,Serni Sergio

Publisher

Springer Science and Business Media LLC

Subject

Urology,Nephrology

Link

http://link.springer.com/content/pdf/10.1007/s11255-012-0135-y.pdf

Reference20 articles.

1. Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, Richie JP, deKernion JB, Walsh PC, Scardino PT, Lange PH, Subong EN, Parson RE, Gasior GH, Loveland KG, Southwick PC (1998) Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 279(19):1542–1547

2. Elgamal AA, Cornillie FJ, Van Poppel HP, Van de Voorde WM, McCabe R, Baert LV (1996) Free-to-total prostate specific antigen ratio as a single test for detection of significant stage T1c prostate cancer. J Urol 156(3):1042–7; discussion 1047-9

3. Aus G, Becker C, Lilja H, Khatami A, Pihl CG, Hugosson J (2003) Free-to-total prostate-specific antigen ratio as a predictor of non-organ-confined prostate cancer (stage pT3). Scand J Urol Nephrol 37(6):466–470

4. Southwick PC, Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, Richie JP, Walsh PC, Scardino PT, Lange PH, Gasior GH, Parson RE, Loveland KG (1999) Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: a prospective multicenter clinical trial. J Urol 162(4):1346–1351

5. Morote J, Encabo G, de Torres IM (2000) Use of percent free prostate-specific antigen as a predictor of the pathological features of clinically localized prostate cancer. Eur Urol 38(2):225–229

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prostate-specific antigen nomogram to predict advanced prostate cancer using area under the receiver operating characteristic curve boosting;Urologic Oncology: Seminars and Original Investigations;2022-04

2. What Can Be Expected from Prostate Cancer Biomarkers A Clinical Perspective;Urologia Internationalis;2017-09-15

3. A Dynamic Model for Predicting Prostate Cancer in Iranian Men Based on a Perceptron Neural Network;International Journal of Cancer Management;2017-03-20

4. ERG rearrangement as a novel marker for predicting the extra-prostatic extension of clinically localised prostate cancer;Oncology Letters;2016-02-25

5. Plasma Levels of E-cadherin and MMP-13 in Prostate Cancer Patients: Correlation with PSA, Testosterone and Pathological Parameters;Tumori Journal;2015-01-03